MCLEAN, Va., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the second quarter ended June 30, 2023. “Appian is leading in AI-based process automation. Our practical and private approach to AI is garnering …
LOS ANGELES, Aug. 03, 2023 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (Nasdaq: PLBY) (the “Company” or “PLBY Group”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, will report …
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- CarGurus, Inc. (Nasdaq: CARG), the No. 1 visited digital auto platform for shopping, buying, and selling new and used vehicles1, today announced that it will delay its second quarter 2023 earnings release …
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Consensus Cloud Solutions, Inc.: On February 22, 2023, the company announced that “as a result of the unintentional errors noted [below], the …
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today …
Reports Record Quarterly Revenue of $279.4 Million, Reflecting 43% Growth Over the Prior Year Period Achieves Record Quarterly Operating Cash Flow of $76.0 Million Raises Full Year Revenue and Earnings Guidance Continuing to See Strong Employer Demand for …
Half-year 2023 key financials Group revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023 Full year 2023 net sales guidance for Jyseleca® lowered to €100-€120 million – 2023 …
Belangrijkste financiële gegevens eerste halfjaar 2023 Groepsomzet van €328,8 miljoen Jyseleca® nettoverkopen van €54,3 miljoen Cash en kortlopende financiële investeringen van €3,9 miljard op 30 juni 2023 Prognose nettoverkopen Jyseleca® voor volledig …
INPEFATM (sotagliflozin) receives FDA approval for the treatment of heart failure INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes LX9211 moving into …
WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on …
WOODBURY, N.Y., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its second quarter and first half of 2023. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its …
– Q2’23 Net Revenue of $135.5 Million, Up 10% Year-over-Year – – Q2’23 GAAP Net Income of $13.0 Million – – Q2’23 Adjusted EBITDA of $85.8 Million, Up 21% Year-over-Year – – Board of Directors has Authorized $50 Million Accelerated Share Repurchase Program …
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced …
On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT …
Reports $462.4 million in total revenue, up 26.2% year-over-year Medicare Advantage enrollment increases to approximately 112,200 members, up 17% year-over-year ORANGE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), a …
OTTAWA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, has scheduled a conference call on Friday, August 11, 2023, at 9:30 a.m. ET to discuss its financial results for …
--Announced positive data from Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and bile acid malabsorption (BAM)-- --Announced topline positive data from Phase 2b …
End of Period Subscribers of 4.1 million Revenues of $226.8 million Operating Income of $26.3 million; excluding the net impact of restructuring charges and acquisition transaction costs, adjusted operating income of $33.9 million Full Year Fiscal 2023 …
• Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with IgA nephropathy (IgAN) • Net product sales of FILSPARI totaled $3.5 million for the …
BARTLETT, Tenn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a technology and telecommunications company focused on the underbanked and underserved, announced today that management will host a live …
06 days 08:30:46
